ISPNO 2020

The 19th International Symposium on Pediatric Neuro-Oncology

December 13(Sun) - 16(Wed), 2020

Karuizawa, Nagano, Japan



Chair: Koichi Ichimura

Vice Chair: Ryo Nishikawa

Venue: Karuizawa Prince Hotel West



Meeting Program

BAYER
より良い
明日へ
患者さんとそのご家族の
「満たされない願い」に応えるため、
革新的な新薬をいち早く
お届けすることが私たちの使命です。
医薬品の開発を通じて人々の
クオリティ・オブ・ライフの向上に
貢献していきます。
バイエル薬品株式会社
http://byl.bayer.co.jp/
Science for a better life
L.JP.MKT.10.2018.1811

販売名：手術用顕微鏡 KINEVO 900
製造販売届出番号：13B1X00119003610

高性能なRobotic Visualization SystemであるKINEVO 900は、
3つの代表的な機能によって、リアルタイムに数多の価値ある知見を提供します。

- **術者が操作するロボティックス**
- **マイクロインスペクションツール QEVO**
  販売名：手術顕微鏡用アシストエンドスコープ QEVO（承認番号：22900BZX00315000）
- **内蔵デジタル3D ビジュアライゼーション**

Visualize the future today!
www.zeiss.com/kinevo

ZEISS

Application image courtesy of Dr. Robert F. Spetzler, Barrow Neurological Institute, Phoenix, Arizona, USA.

ISPNO 2020

The 19th International Symposium on Pediatric Neuro-Oncology

December 13(Sun) - 16(Wed), 2020

Karuizawa, Nagano, Japan

Chair: Koichi Ichimura
Vice Chair: Ryo Nishikawa
Venue: Karuizawa Prince Hotel West

Program

ISPNO 2020

The 19th International Symposium on Pediatric Neuro-Oncology

Contents

Welcome Message	4
Committees	5
Conference Information	7
ISPNO 2020 Award Recipients	11
Main Program (On Site & Live Streaming Program)	14
On-demand Program	27
Sponsors	28

Welcome Message

Dear Friends and Colleagues,

It is our great pleasure to welcome you to The 19th International Symposium on Pediatric Neuro-Oncology (ISPNO 2020). We are tremendously honored to host ISPNO, 35 years after the very first ISPNO was held in Japan.

The COVID-19 pandemics have changed the world in 2020. It has profoundly affected our way of living and activities. Nonetheless, it will not stop our science. ISPNO 2020, originally planned in June, is now held in December at Karuizawa Prince Hotel West as a hybrid meeting. It is a great opportunity for everyone to join the symposium from home or workplace without having to travel!

We have a fantastic line-up of 82 invited lecturers who will give a live talk and Q&A in the Main Program, which will be live streamed. The live streaming contents will be posted in the On-Demand Program after the symposium. In the On-Demand Program, all 858 accepted abstracts and 12 Education Day lectures will be made viewable from December 13, 2020 until February 13, 2021 for all registrants. In addition, we have launched the ISPNO Award scheme to recognize the long-standing contribution of people who devoted their life for the development of pediatric neuro-oncology.

My special thanks to Joan Slaughter of the Morgan Adams Foundation who gave me invaluable advice on fundraising, and to Linda Greer of the Society for Neuro-Oncology whose devotion was truly inspirational. We thank all invited lecturers who agreed to give live online lectures despite the time difference and all Education Day lecturers and abstract authors who stuck with us upon the change of the format. We thank Prof. Kamibeppu and Dr. Sato for organizing the nursing session, Ms. Moue and Mr. Yamashita for organizing the Family Day, and all NPOs, industries, The Rotary Club and individual donors who made this incredible endeavor possible despite the unprecedented circumstances. Last but not least, we thank the members of staff who helped us throughout the preparation and the symposium.

Together, we will move pediatric neuro-oncology forward. Enjoy the Symposium!

Koichi Ichimura, M.D., Ph.D.
Chair of ISPNO2020
Chief
Division of Brain Tumor Translational Research
National Cancer Center Research Institute

Ryo Nishikawa, M.D., Ph.D.
Vice Chair of ISPNO2020
Professor
Department of Neuro-Oncology/ Neurosurgery
Saitama Medical University International Medical Center

ISPNO2020 Committee

ISPNO2020 Organizing Committee

❖ Honorary Chairs

Kintomo Takakura †
Professor Emeritus, The University of Tokyo
† In Memory

Masao Matsutani
Professor Emeritus, Saitama Medical University
Director, Gotanda Rehabilitation Hospital

Takamasa Kayama
Past-President, Japan Neurosurgical Society
President Emeritus, National Cancer Center Hospital
Professor, Faculty of Medicine, Yamagata University

Hajime Arai
Executive President, Japan Neurological Society
Professor and Chairman, Department of Neurosurgery
Faculty of Medicine, Juntendo University

❖ Chair

Koichi Ichimura
Chief, Division of Brain Tumor Translational Research
National Cancer Center Research Institute

❖ Vice Chair

Ryo Nishikawa
Professor, Department of Neuro-Oncology/Neurosurgery
Saitama Medical University International Medical Center

❖ Nursing Session Chair

Kiyoko Kamibeppu
Professor, Department of Family Nursing, Division of Health Sciences and Nursing,
Graduate School of Medicine, The University of Tokyo

❖ Secretary General

Keita Terashima
Head, Division of Neuro-Oncology, Children's Cancer Center
National Center for Child Health and Development

❖ Deputy Secretary General

Tomonari Suzuki
Associate Professor, Department of Neuro-Oncology/ Neurosurgery
Saitama Medical University International Medical Center

International Organizing Committee

*In alphabetical order, by last name

❖ Chair

Roger Packer (USA)

❖ Members

Eric Bouffet (Canada)
Sidnei Epelman (Brazil)
Nick Foreman (USA)
Amar Gajjar (USA)
Richard Gilbertson (UK)
Stewart Goldman (USA)
Michael Handler (USA)
Annie Huang (Canada)
Rakesh Jalali (India)
Steward Kellie (Australia)
Mark Kieran (USA)
Chae-Yong Kim (Korea)
Masao Matsutani (Japan)
Ludmila Papusha (Russia)
Stephan Pfister (Germany)
Barry Pizer (UK)
Stefan Rutkowski (Germany)
Chitra Sarkar (India)
Irene Slavc (Austria)
Mark Souweidane (USA)
Tai Tong Wong (Taipei)

ISPNO 2020 Committee

Local Organizing Committee

*In alphabetical order, by last name

Yoshiki Arakawa	(Kyoto University)
Akio Asai	(Kansai Medical University)
Hiroshi Fuji	(National Center for Child Health and Development)
Yukihiko Fujii	(University of Niigata)
Takamitsu Fujimaki	(Saitama Medical University Hospital)
Akira Gomi	(Jichi Medical University)
Junichi Hara	(Osaka City General Hospital)
Naoya Hashimoto	(Kyoto Prefectural University of Medicine)
Yuichi Hirose	(Fujita Health University)
Tomotsugu Ichikawa	(Kagawa Prefectural Central Hospital)
Yonehiro Kanemura	(National Hospital Organization Osaka National Hospital)
Atsushi Kawamura	(Hyogo Prefectural Kobe Children's Hospital)
Katsuyoshi Koh	(Saitama Children's Medical Center)
Yoshiyuki Kosaka	(Hyogo Prefectural Kobe Children's Hospital)
Toshihiro Kumabe	(Kitasato University)
Katsuya Maebayashi	(Nippon Medical School)
Kazuhiko Mishima	(Saitama Medical University International Medical Center)
Nobuhito Morota	(Kitasato University School of Medicine)
Akitake Mukasa	(Kumamoto University)
Yoshihiro Muragaki	(Tokyo Women's Medical University)
Motoo Nagane	(Kyorin University)
Tatsuya Nagashima	(Hyogo Prefecture Hospital)
Mitsutoshi Nakada	(Kanazawa University)
Hideo Nakamura	(Kurume University)
Yozo Nakazawa	(Shinshu University)
Yoshitaka Narita	(National Cancer Center Hospital)
Atsushi Natsume	(Nagoya University)
Sumihito Nobusawa	(Gunma University)
Hideki Ogiwara	(National Center for Child Health and Development)
Hiroaki Sakamoto	(Osaka City General Hospital)
Hikaru Sasaki	(Keio University)
Yuta Shibamoto	(Nagoya City University)
Akira Shimada	(Okayama University Hospital)
Toshinori Soejima	(Hyogo Cancer Center)
Yukihiko Sonoda	(Yamagata University Faculty of Medicine)
Kazuhiko Sugiyama	(Hiroshima University)
Takashi Taga	(Shiga University)
Hideo Takeshima	(University of Miyazaki)
Tetsuya Takimoto	(National Center for Child Health and Development)
Takashi Tamiya	(Kagawa University)
Tomoki Todo	(The Institute of Medical Science, The University of Tokyo)
Yoshiyuki Tsutsumi	(National Center for Child Health and Development)
Tetsuya Ueba	(Kochi Medical School)
Keisuke Ueki	(Dokkyo University)
Toshihiko Wakabayashi	(Nagoya University)
Yuko Watanabe	(National Cancer Center Hospital)
Tetsuya Yamamoto	(Yokohama City University Hospital)
Takaaki Yanagisawa	(Jikei University School of Medicine)
Koji Yoshimoto	(Kagoshima University)

Secretariat of ISPNO 2020

c/o Convex Inc.
Toranomon Waiko Bldg., 5-12-1 Toranomon, Minato-ku, Tokyo 105-0001 Japan
Tel: +81-3-5425-1602 Fax: +81-3-5425-1605
E-mail: ispno2020@convex.co.jp

Date: December 13 (Sun) – 16 (Wed), 2020
Venue: Karuizawa Prince Hotel West
Karuizawa-machi, Kitasaku-gun, Nagano
389-0193 Japan
Tel: +81-267-42-1111

Venue Map

Karuizawa Prince Hotel West



Registration Desk

The Registration Desk is located at the banquet lobby of Karuizawa Prince Hotel West and is open during the following hours:

December 13 (Sunday)	08:30-20:00
December 14 (Monday)	06:30-22:00
December 15 (Tuesday)	06:30-19:30
December 16 (Wednesday)	06:30-14:00

Registration Fee (For On-site only)

Category	Price
Delegate 1	JPY 70,000
Delegate 2/Student/Trainee/Healthcare Partner	JPY 30,000
Accompanying Person (Spouse, Family Member)	JPY 3,000
Gala Dinner	JPY 15,000

*For Gala Dinner, seating is limited and on a first-come, first-served basis.

Payment Method

Payment must be made by credit card.
Accepted credit cards are VISA, MasterCard, Diners Club, AMEX, and JCB.

Name Badges and Program Book

You are requested to come to the Registration Desk to pick up your conference kit within the above time frame. The name badge is mandatory for access to all sessions, social events and exhibitions during the conference.

Publication of Abstracts

All abstracts accepted for Oral and Poster Presentations at ISPNO 2020 will be available online and accessible from our website. Scan the QR below to access E-Abstracts.

URL https://app.oxfordabstracts.com/events/1051/program-app/program

Internet Access

Free WiFi is available in the Karuizawa Prince Hotel West at the following places:
+ Session Room
+ Lounge “KURUMI”
+ Lobby

Coffee Break

Coffee and snacks will be served at the lounge “KURUMI”. A drink counter with complimentary drinks will be set up. There are power sockets available for use. Refresh and recharge while you observe the live sessions.

Lunch

Lunch boxes will be available at the Session Room during the following hours:

December 14 (Monday)	12:00-12:50
December 15 (Tuesday)	12:00-13:00
December 16 (Wednesday)	12:30-13:30

Social Events

-Welcome Reception

Date: Sunday, December 13
Time: 18:00-20:00
Place: Chikuma, Karuizawa Prince Hotel West
Fee: Included in the registration fee

-Gala Dinner

Date: Tuesday, December 15
Time: 19:30-21:30
Place: Asama, Karuizawa Prince Hotel West
Fee: JPY 15,000
*Seating is limited and on a first-come, first-served basis.

Safety and Security

Please do not leave valuable things unattended at any time, whether inside or outside session. We strongly recommend that you use your hotel safety deposit box for your valuables.

Symposium Etiquette

- Participants are advised not to photograph or video and voice recording any sessions without the author's consent. Participants are also advised to obtain consent from authors before citing any of their work presented at the symposium.
- Switch your mobile phone to silent mode or turn it off completely during the sessions. Turn off the volume of other electronic devices such as, PC and DVD, and reduce screen brightness. We appreciate your cooperation.

Prevention Measures against COVID-19

1. If you have a fever or COVID-like symptoms, refrain from attending the symposium.
2. Wear your facemask.
3. Hand sanitizers are placed around the symposium venue. Clean and disinfect your hands thoroughly.
4. Follow the rules and regulations of the facility.
5. Air ventilation is important in preventing the coronavirus from spreading indoors; due to this, there might be noises and we apologize for the inconvenience.

Contact

Secretariat of ISPNO 2020
c/o Convex Inc.
Toranomon Waiko Bldg., 5-12-1 Toranomon, Minato-ku, Tokyo 105-0001 Japan
Tel: +81-3-5425-1602 Fax: +81-3-5425-1605
E-mail: ispno2020@convex.co.jp

Instructions for Presentation On-site

1. PC Preview Desk is located next to the Session Room.
2. Please bring your PC or presentation data (PPT) to the PC Preview Desk at least 30 minutes prior to your presentation to register and submit it to test the connection and view your file.
3. All presentations will be done on PC. Please use the following settings in PowerPoint for your presentation slides:
   ・16:9 aspect ratio
   ・Refrain from using Presenter View
4. For Windows users, please bring your presentation data in the form of CD-R or USB Flash memory; or your own PC. For Macintosh users, please bring your own PC for your presentation.
5. PCs with Windows 10 and PowerPoint 2010, 2013 and 2016 are to be used.
6. If you are using your own PC, please confirm whether your PC has an RGB port (mini D-sub 15 pin type) or HDMI port to connect to the projector. If you use a different type of RGB jack to connect to an external monitor, please bring it with you. Please bring your PC charger and adapter in case the battery runs out during your presentation.



7. Please use the mouse on the podium for your presentation. You are required to handle your data yourself, using the mouse connected to the PC.
8. The copied data for your presentation will be deleted by the secretariat after the symposium.

Disclosure of Conflicts of Interest (COI)

All presenters must declare their COI status on the first presentation slide (or immediately after the title and presenters) as shown in the example below:

e.g.1)

ISPNO 2020

COI Declaration

Affiliation Name (all presenters)

The presenter has no conflict of interest with any corporate organizations relating to this presentation.

e.g.2)

ISPNO 2020

COI Declaration

Affiliation Name (all presenters)

The presenter has potential conflict of interest with the corporate organizations below:

Name of organizations

Lifetime Achievement Award

Roger J. Packer, MD

It is with great enthusiasm that the members of the ISPNO community have decide to offer this first Lifetime Achievement Award to Dr. Roger Packer.
Dr. Packer started his career in Philadelphia, in 1981. He very quickly became one of the leaders of this small community of oncology specialists interested in pediatric brain tumors. Over the years, he came to influence the management of most pediatric brain tumors, many of the protocols he developed being commonly referred to as the “Packer regimens”.
The description of Dr. Packer’s multiple contributions to the field of pediatric neuro-oncology could span entire chapters. He has been and still remains an active, passionate and dedicated member of the COG and several national or international networks, such as the Neurofibromatosis Consortium or the Pediatric Brain Tumor Consortium. He is a true leader and generates ideas that frequently translate into innovative protocols or national/international collaborations. As we all know, Dr. Packer’s career is also strongly associated with the story of the ISPNO meeting and he has contributed to the development of an international paediatric neuro-oncology network.
Each and every member of the pediatric neuro-oncology community overwhelmingly shares the opinion that Dr Packer’s unparalleled contribution to his field should be recognized at this time of his career and it is really a pleasure and a privilege to offer him this Award at the ISPNO Meeting 2020.

Presented by Eric Bouffet

Award Recipient Profile:

Roger J. Packer, MD

Dr. Roger J. Packer is the Senior Vice President of the Center for Neuroscience and Behavioral Medicine and Director of the Brain Tumor Institute and the Gilbert Family Neurofibromatosis Institute at Children's National Hospital in Washington, DC. His career is focused on the care of children with brain tumors including the development of prospective clinical trials for children with medulloblastoma, other embryonal tumors, and with high and low-grade gliomas. He has and continues to lead efforts in multiple brain tumor and neurofibromatosis consortiums and the protocols Dr. Packer developed for medulloblastoma and low-grade glioma remain international standards. He has published well over 400 original article and 350 chapters and books. He was one of the founders of ISPNO, co-chairing the first meeting in the United States in Seattle in 1989, while also chairing ISPNO in Philadelphia (1990) and Washington, D.C. (1996).

Lifetime Contribution to Asian Neuro-Oncology Community Award

Tai-Tong Wong, MD

Dr. Tai-Tong Wong represents one of the most senior and well-respected pediatric brain tumor specialist and neurosurgeon in Taiwan and Asia. He completed his undergraduate medical degree in 1973 from the NDMC and then pursued neurosurgical training at Taipei VGH (1973-1978) followed by a pediatric neurosurgery fellowship at SickKids Hospital, Canada (1980). He returned to Taiwan where he helped drive innovative multi-disciplinary approaches and pediatric brain tumor research and trained the first generation of pediatric neuro-surgeons in Taiwan. Most recently (2015), he became the director of the pediatric brain tumor program of Taipei Cancer Center at TMUH/TMU where he maintains a very busy consult service and directs a brain tumor research laboratory. Recently, he led and became founding president of the Taiwan Pediatric Brain Tumor Consortium (TPBTC).
In addition to his home country, Dr Wong has also played a critical role in the development of pediatric neurosurgery and neuro-oncology in Asia through international training initiatives and leadership in multiple international organizations. In addition to founding presidencies of TSNO (2003-2005), TSPN (2008-2010), he has served as president of ASPN (2015-2017) and ISPN (2009-2010). He has been an active organizer of multiple local and several international congresses including the 4th Congress of ASNO (2005), the 34th ISPN annual meeting (2006), and 2nd Asian CNS GCT Conference (2016). The ISPNO 2020 Award for Lifetime contribution to Asian Neuro-Oncology Community recognizes the invaluable career-long commitment of Dr Wong to promoting pediatric neuro-surgery and Neuro-oncology in Asia.

Presented by Annie Huang

Award Recipient Profile:

Tai-Tong Wong, MD

Pediatric Brain Tumor Program and Pediatric Neurosurgery, Department of Neurosurgery, Taipei Medical University Hospital

Dr. Tai-Tong Wong is currently staff and professor of pediatric neurosurgery and director of pediatric brain tumor program of Taipei Cancer Center at TMUH/TMU (since 2015). He graduated from NDMC (1973) and received neurosurgical and pediatric neurosurgical training in Taipei VGH (1973-1978) and HSC Toronto (clinical and research fellow, 1980), respectively. He dedicates for team treatment and research of pediatric brain tumors since then. He has been the first president of TSNO (2003-2005), TSPN (2008-2010), AASPN (2015-2017), TPBTC (2020-2023); president of ISPN (2009-2010); and pediatric neurosurgery committee chairman of WFNS (2010-2013). He had also hosted and organized international congresses including the 4th Congress of ASNO (2005), the 34th ISPN annual meeting (2006), and 2nd Asian CNS GCT Conference (2016).

Abbreviations: TMUH – Taipei Medical University Hospital; TMU – Taipei Medical University; NDMC – National Defense Medical Center; Taipei VGH – Taipei Veterans General Hospital; HSC Toronto – Hospital for Sick Children Toronto; TSNO – Taiwan Society for Neuro-Oncology; TSPN – Taiwan Society for Pediatric Neurosurgery; AASPN – Asian Australasian Society for Pediatric Neurosurgery; WFNS – World Federation of Neurological Society; ASNO – Asian Society for Neuro-Oncology; ISPN – International Society for Pediatric Neurosurgery; CNS GCT – Central Nervous System Germ cell Tumor.

Pediatric Neuro-Oncology Community Service Award

Angela Dickson, MBE
Neil Dickson, MBE

Neil and Angela Dickson have made a significant contribution to neuro-oncology in the last 24 years. Inspired by the loss of their beautiful daughter Samantha, and recognising that there was not enough research into brain tumours, they worked tirelessly to ensure that high quality research was pursued across the UK, and around the world.
Among other achievements, they've funded work that led to the discovery of the medulloblastoma subtypes, and steadfastly supported Head Smart, the award winning campaign that decreased diagnosis time for UK children with a brain tumour and in 2012 were integral in the merger which formed The Brain Tumour Charity as a global funder of research in the field.

Presented by Barry Pizer

Award Recipient Profile:

Angela Dickson, MBE
Founder Trustee, The Brain Tumour Charity

Neil Dickson, MBE
Founder and Vice chair of Trustee, The Brain Tumour Charity

Neil and Angela founded the Samantha Dickson Brain Tumour Trust in 1996, since renamed The Brain Tumour Charity. It is one of the largest funders of brain tumour research in the World. Being passionate about International collaboration, they have been supporters of ISPNO, attended seven conferences and have been silver and gold sponsors. We are delighted to accept this Award from ISPNO in recognition of our contribution towards helping find a cure for brain tumours.

December 13 (Sunday)

9:00 - 11:20 **Nursing Session**
Moderator : *Kiyoko Kamibeppu (Japan)*

9:00 - 9:05 **Introduction**
NUR-IS-01 Kiyoko Kamibeppu (Japan)

9:10 - 9:50 **Education Support for Pediatric Brain Tumor Patients**
NUR-IS-02 Chie Matsuo (Japan)

9:50 - 10:00 **Break**

10:00 - 11:20 **Cognitive Function and Education Support in each Country**
Moderators : *Pamela S. Hinds (USA), Iori Sato (Japan)*
10:00 - 10:25 Child and family concerns related to cognitive function after treatment for pediatric brain tumor
NUR-IS-03 Naoko Takenouchi (Japan)
10:25-10:50 Supporting cognition and learning in pediatric brain tumor patients:
NUR-IS-04 The role of executive functioning surveillance and intervention
Kristi Hardy (USA)
10:50 - 11:00 Commentary
NUR-IS-05 Pamela S. Hinds (USA)
11:00 - 11:20 Discussion
NUR-D-06

11:20 - 12:15 **Family Day Session**
Sponsored by: American Family Life Assurance Co. of Columbus
11:20 - 12:00 Pediatric Brain Tumor Patient Advocates in Japan
FAM-IS-01 Yuko Moue (Japan)
12:00 - 12:15 Around the world in 15 minutes: innovative approaches to support, treatment and care
FAM-IS-02 of pediatric brain tumour patients
Kathy Oliver (UK)

18:00 - 20:00 **Welcome Ceremony**

December 14 (Monday)

7:00 - 8:00 **Symposium 1 NGS - where do we go from here?**

Sponsored by: American Brain Tumor Association

Moderator : *Ryo Nishikawa (Japan)*

7:00 - 7:20 *SYMP1-IS-01* Learning from non-coding mutations in cancer genomes
Hiromichi Suzuki (Canada)

7:20 - 7:40 *SYMP1-IS-02* Developmental and oncogenic programs in pediatric ependymoma revealed by single-cell RNAseq
Mariella G. Filbin (USA)

7:40 - 8:00 *SYMP1-IS-03* Context matters: Cell of origin dependencies in histone H3.3G34-mutant gliomas
Claudia Kleinman (Canada)

8:00 - 8:30 **Opening Ceremony**

OPE-PE-01 Opening Performance
Kan Fukuhara (Japanese flute), Soh Katada (Japanese percussion)

OPE-C-02 Opening Speech
Koichi Ichimura (Japan)

8:30 - 8:40 **Award Ceremony 1 Lifetime Achievement Award**

Sponsored by: The Childhood Brain Tumor Foundation

Moderator : *Koichi Ichimura (Japan)*

Presenter: Eric Bouffet (Canada)

OPE-A-04 Acceptance Speech
Roger Packer (USA)

8:40 - 9:10 **Opening Keynote Lecture**

Sponsored by: The Childhood Brain Tumor Foundation

Moderator : *Koichi Ichimura (Japan)*

OPE-IS-03 Pediatric neuro-oncology: perspectives of the new decade
Roger Packer (USA)

9:10 - 10:00 **Late-breaking Session Pediatric Neuro-Oncology and COVID-19**

Moderator : *Takaaki Yanagisawa (Japan)*

9:10 - 9:25 *COV-IS-01* Characteristics of SARS-CoV-2 in 64 Children with CNS Tumors: A Report from the SIOP/St. Jude Children's Research Hospital (SJCRH) Global COVID-19 Childhood Cancer Registry
Eric Bouffet (Canada)

9:25 - 9:35 *COV-O-02* Vinblastine monotherapy induction for localised CNS germinoma during the COVID-19 pandemic
Matthew Murray (UK)

9:35 - 9:45 *COV-O-03* Impact of COVID-19 on therapy provision for children with CNS tumours
Helen Hartley (UK)

9:45 - 10:00 *COV-QA-04* Q&A

10:00 - 10:30 **Special Lecture 1**

Sponsored by: Nationwide Children's Hospital

Moderator : *KeitaTerashima (Japan)*

SL1-IS-01 Genomics and Immunogenomics of Progression in Pediatric CNS Cancers
Elaine Mardis (USA)

10:30 - 11:00 **Special Lecture 2**

Sponsored by: Thermo Fisher Scientific

Moderator : *KeitaTerashima (Japan)*

SL2-IS-02 Pediatric precision neuro-oncology: 2020 status report
Will Parsons (USA)

11:00 - 12:00 **Sponsored Seminar 1**

Sponsored by: Chugai Pharmaceutical Co., Ltd.

Moderator: *KeitaTerashima (Japan)*

SS-IS-LV-01 Targeted Therapy for CNS Tumors (STARTRK Trial) (No On-Demand Program)
Amar Gajjar (USA)

12:00 - 12:50 **Luncheon Seminar 1**

Sponsored by: Canon Medical Systems Corporation

12:00 - 12:40 *LS-IS-02* Hands-on Experience Program for Pediatric Cancer Patients and Their Families: Scan It! See through it! Seeing is exciting!
Akiko Higuchi (Japan)

12:40 - 12:50 *LS-C-03* Commentary
Kathy Oliver (UK)

12:50 - 13:00 **Break**

13:00 - 13:10 **Award Ceremony 2**
Lifetime Contribution to Asian Neuro-Oncology Community Award

Sponsored by: The Childhood Brain Tumor Foundation

Moderator : *Koichi Ichimura (Japan)*

Presenter: Annie Huang (Canada)

OPE-A-05 Acceptance Speech
Tai-Tong Wong (Taiwan)

13:10 - 15:00 **Forum 1 Pediatric Neuro-Oncology in Asia and other Countries**

Moderator : *Ryo Nishikawa (Japan)*

13:10 - 13:20	The global burden of childhood central nervous system (CNS) cancer
FRM1-IS-01	Jonathan Finlay (USA)
13:20 - 13:30	Pediatric Neuro-Oncology in China
FRM1-IS-02	Zhong-Ping Chen (China)
13:30 - 13:40	Clinical trial results and current treatment trends for medulloblastoma in Korea
FRM1-IS-03	Jung Woo Han (Korea)
13:40 - 13:50	TBA
FRM1-IS-04	Suradej Hongen (Thailand)
13:50 - 14:00	Paediatric Brain Tumors in a Tertiary Government Hospital in the Philippine Setting
FRM1-IS-05	Annabell Chua (Philippines)
14:00 - 14:10	Epidemiology, Treatment, and Outcomes of Medulloblastoma: The Indian Experience
FRM1-IS-06	Tejpal Gupta (India)
14:10 - 14:20	Diagnostic and treatment results of patients with brain tumors in D. Rogachev
FRM1-IS-07	National Medical Research Center Ludmila Papusha (Russia)
14:20 - 14:30	Free access for molecular diagnosis in medulloblastoma in Brazil and Latin America
FRM1-IS-08	- preliminary results Sidnei Epelman (Brazil)
14:30 - 14:40	Pediatric intracranial germ cell tumors and medulloblastoma; the Jordanian experience
FRM1-IS-09	Nisreen Amayiri (Jordan)
14:40 - 15:00	Panel Discussion and Wrap up
FRM1-QA-10	R. Nishikawa (Japan) /J. Finlay (USA) / G. Dhall (USA) / E. Bouffet (Canada) / U. Bartels (Canada)

15:00 - 15:30 **Afternoon Seminar 1**

Long-term Survivorship Challenges and Novel Mitigation Strategies in Childhood Brain Tumours

Sponsored by: Apollo Hospitals Enterprise Limited

Moderator : *Ryo Nishikawa (Japan)*

AFT1-IS-11	Preservation of cognition and neuro-psychological function after modern photon and proton beam irradiation for childhood CNS tumours Rakesh Jalali (India)

15:30 - 16:00 **Break**

16:00 - 16:20 **Keynote 1 Palliative Care**

Moderator : *Atsushi Manabe (Japan)*

SOC-IS-01	Pediatric Palliative Care Nobuyuki Yotani (Japan)

16:20 - 17:00 **Symposium 2 Preclinical Model for Pediatric Brain Tumors**

Sponsored by: St. Baldrick's Foundation

Moderator : *Daisuke Kawauchi (Japan)*

16:20 - 16:40 *SYMP2-IS-04* Human pluripotent stem cell-derived brain tumor model uncovers the embryonic stem cell signature as a key driver in atypical teratoid/rhabdoid tumor
Yukinori Terada (Japan)

16:40 - 17:00 *SYMP2-IS-05* Future prospective in preclinical studies of pediatric brain tumors using mouse molecular genetic technologies
Daisuke Kawauchi (Japan)

17:00 - 17:10 **Award Ceremony 3 Pediatric Neuro-Oncology Community Service Award**

Sponsored by: The Childhood Brain Tumor Foundation

Moderator : *Koichi Ichimura (Japan)*

Presenter: Barry Pizer (UK)

OPE-A-06 Acceptance Speech
Angela & Neil Dickson (UK)

17:10 - 17:40 **Special Lecture 3**

Sponsored by: The Tokyo Biochemical Research Foundation

Moderator : *Koichi Ichimura (Japan)*

SL3-IS-03 Will we ever cure cancer?
Richard Gilbertson (UK)

17:40 - 18:00 **Symposium 3 Precision Medicine**

Moderator : *Katsuyoshi Koh (Japan)*

SYMP3-IS-08 PRECISION MEDICINE: the challenges beyond the discovery
Jacques Grill (France)

18:00 - 18:25 **Keynote 2 Low Grade Glioma (basic)**

Sponsored by: The PLGA Fund at the Pediatric Brain Tumor Foundation

Moderator : *Katsuyoshi Koh (Japan)*

LGGB-IS-01 Pediatric low-grade glioma: State-of-the-art in 2020
David Jones (Germany)

18:25 - 18:50 **Keynote 3 HGG (basic)**

Moderator : *Katsuyoshi Koh (Japan)*

HGGB-IS-01 The diversity of what we call a 'high grade glioma' in children and young adults
Chris Jones (UK)

18:50 - 19:15 **Keynote 4 Ependymoma (basic)**

Sponsored by: Collaborative Ependymoma Research Network Foundation

Moderator : *Katsuyoshi Koh (Japan)*

EPEB-IS-01 Ependymoma, an increasingly less enigmatic disease
Kristian Pajtler (Germany)

19:15 - 19:40 **Keynote 5 AT/RT**

Moderator : *Katsuyoshi Koh (Japan)*

ATRB-IS-01 ATRT – update on biology, subgroups, targets, and potential clinical implications
Marcel Kool (Germany)

19:40 - 21:30 **Break**

21:30 - 22:00 **Special Lecture 4**

Moderator : *Daisuke Kawauchi (Japan)*

SL4-IS-04 PFA ependymoma – a metabolic monster
Michael Taylor (Canada)

22:00 - 23:30 **Forum 2 Preserving and Enhancing QoL and Function**

Moderator : *Shota Tanaka (Japan)*

22:00 - 22:20 Early global neurologic rehabilitation in pediatric patients with brain tumors
FRM2-IS-01 Andrés Morales La Madrid (Spain)

22:20 - 22:40 Practical tools for enhancing functional outcomes in neuro-oncology
FRM2-IS-02 Nathan Rosenberg (USA)

22:40 - 23:00 Radiotherapy Methods to Preserve Quality of Life and Organ Function in Pediatric
FRM2-IS-03 Cancer Patients
Joshua Palmer (USA)

23:00 - 23:20 Palliative Care approach to optimize function and quality of life on patients with brain tumor
FRM2-IS-04 Paola Genovese (USA)

23:20 - 23:30 Q&A
FRM2-QA-05 ***Moderators :*** *Nathan Rosenberg (USA), Shota Tanaka (Japan)*

December 15 (Tuesday)

7:00 - 7:25 **Keynote 6 ETMR and other Embryonal Tumors**

Moderator : *Ryo Nishikawa (Japan)*

ETMB-IS-01 Understanding the clinical and biological landscape of ETMRs
Annie Huang (Canada)

7:25 - 7:50 **Keynote 7 Craniopharyngioma**

Moderator : *Ryo Nishikawa (Japan)*

CRA-IS-01 Treatment Challenges of Adamantinomatous Craniopharyngioma
Ute Bartels (Canada)

7:50 - 8:15 **Special Lecture 5**

Moderator : *Ryo Nishikawa (Japan)*

SL5-IS-05 Replication repair deficiency and hypermutation in childhood brain tumors: Insights on germline and somatic mutagenesis
Uri Tabori (Canada)

8:15 - 8:40 **Keynote 8 Low Grade Glioma (clinical)**

Sponsored by: The PLGA Fund at the Pediatric Brain Tumor Foundation

Moderator : *Takaaki Yanagisawa (Japan)*

LGGC-IS-01 Paediatric Low Grade Gliomas: clinical management
Eric Bouffet (Canada)

8:40 - 9:05 **Keynote 9 DIPG**

Moderator : *Ryo Nishikawa (Japan)*

DIPB-IS-01 Molecular pathways and therapeutic opportunities in DIPG
Nada Jabado (Canada)

9:05 - 9:30 **Keynote 10 HGG (clinical)**

Sponsored by: The Morgan Adams Foundation

Moderator : *Ryo Nishikawa (Japan)*

HGGC-IS-01 Translating the advancing biology of CNS high-grade gliomas into actual patient benefit
Mark Kieran (USA)

9:30 - 9:55 **Late-breaking Lecture Ependymoma ACNS0831 Clinical Trial**

Sponsored by: The Robert Connor Dawes Foundation

Moderator : *Ryo Nishikawa (Japan)*

EPEC-O-02 ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
Amy Smith (USA)

9:55 - 10:20 **Keynote 11 Ependymoma (clinical)**

Sponsored by: The Robert Connor Dawes Foundation

Moderator : *Ryo Nishikawa (Japan)*

EPEC-IS-01 Posterior Fossa Ependymoma (PF EPN): Reaching for Effective Therapy while exploring new Biology
Nicholas Foreman (USA)

10:20 - 10:45 **Keynote 12**
Pathology and Molecular Classification (WHO Classification and cIMPACT-NOW)

Sponsored by Illumina K.K.

Moderator : *Takashi Komori (Japan)*

PAT-IS-01 Histopathology and molecular pathology in the diagnosis of pediatric CNS tumors - WHO Classification, Edition 5
David Ellison (USA)

10:45 - 11:10 **Keynote 13 Epidemiology**

Moderator : *Yukihiko Sonoda (Japan)*

EPI-IS-01 Know the facts! An update on causes and risk factors for childhood brain tumors
Jill Barnholtz-Sloan (USA)

11:10 - 11:50 **Special Lecture 6**

Sponsored by: THERABIOPHARMA Inc.

Moderator : *Yukihiko Sonoda (Japan)*

FIB-IS-01 Neurofibromatosis type 1
Murali Chintagumpala (USA)

11:50 - 12:00 **Break**

12:00 - 13:00 **Luncheon Seminar 2**

Sponsored by: ONO PHARMACEUTICAL CO., LTD.

Moderator : *Ryo Nishikawa (Japan)*

LS-IS-LV-01 Molecular pathogenesis and treatment of primary central nervous system lymphoma: Evidence and perspectives (No On-Demand Program)
Motoo Nagane (Japan)

13:00 - 14:20 **CNS Germ Cell Tumors Session**

Sponsored by: The Japan Pediatric Brain Tumor Research Fund

Moderator : *Hirokazu Takami (Japan)*

13:00 - 13:30 **Special Lecture 7**

CNSB-IS-01 (basic) Mechanism and In Vitro Reconstitution of Mammalian Germ-Cell Development
Mitinori Saitou (Japan)

13:30 - 13:55 **Keynote 14**

CNSC-IS-01 (clinical) Treatment of CNS germ cell tumors, from the past to the future
Masao Matsutani (Japan)

13:55 - 14:20 **Keynote 15**

CNSC-IS-02 (clinical) Korean studies in intracranial germ cell tumors
Chang-Ok Suh (Korea)

14:20 - 14:50 **Special Lecture 8**

Moderator : *Hirokazu Takami (Japan)*

SL8-IS-06 Deciphering the origin of somatic mutations in brain tumors
Jeong Ho Lee (Korea)

14:50 - 15:20 **Special Lecture 9**

Moderator : *Koichi Ichimura (Japan)*

SL9-IS-07 Japanese platform for cancer genomic medicine; a new hope for children
Hiroyuki Mano (Japan)

15:20 - 15:50 **Afternoon Seminar 2 Nanopore Sequencing**

Moderator : *Koichi Ichimura (Japan)*

SS-IS-01 Characterization of complicated structural variants with local copy-number changes in cancer genomes using PromethION
Yutaka Suzuki (Japan)

15:50 - 16:20 **Meet-the-Experts**

Sponsored by: Medical U&A, Inc.

Moderator : *Tomonari Suzuki (Japan)*

EXP-IS-12 Endoscopic endonasal resection of sellar and parasellar lesions for pediatric and adolescent patients
Yudo Ishii (Japan)

16:20 - 17:10 **Neurosurgery Session**

Moderator : *Yukihiko Sonoda (Japan)*

16:20 - 16:45 **Keynote 16**

NEU-IS-01 Overcoming the limitation of current treatment for malignant pediatric brain tumors: updating neurosurgical points of views

Chae-Yong Kim (Korea)

16:45 - 17:10 **Keynote 17**

NEU-IS-02 Surgical challenges and solutions for improving surgical outcome in Ependymoma Surgery

Conor Mallucci (UK)

17:10 - 17:40 **Special Lecture 10**

Sponsored by: Bristol Myers Squibb

Moderator : *Ryo Nishikawa (Japan)*

SL10-IS-08 Hereditary predisposition to childhood cancer

Stefan Pfister (Germany)

17:40 - 19:20 **Forum 3 Posterior Fossa Syndrome**

Moderators : *Barry Pizer (UK), Ryo Nishikawa (Japan)*

17:40 - 18:00 Symposium on cerebellar mutism syndrome

FRM3-IS-01 Barry Pizer (UK)

18:00 - 18:20 Radiology of Cerebellar Mutism Syndrome

FRM3-IS-02 Shivaram Avula (UK)

18:20 - 18:40 Surgical aspects to minimise cerebellar mutism syndrome

FRM3-IS-03 - have we made any progress?

Conor Mallucci (UK)

18:40 - 18:50 "The Nordic-European study of the cerebellar mutism syndrome"

FRM3-IS-04 – Establishing the Study

Astrid Sehested (Denmark)

18:50 - 19:00 Cerebellar Mutism Syndrome and the surgical risk factors: a prospective multicentre

FRM3-O-05 study of 500 patients undergoing tumour surgery in the posterior fossa

Jonathan Kjær Grønbæk (Denmark)

19:00 - 19:10 Future Directions for Research in Cerebellar Mutism Syndrome

FRM3-IS-06 Astrid Sehested (Denmark)

19:10 - 19:20 Panel discussion/Q&A

FRM3-QA-07

19:30 - 21:30 **Evening Seminar**

December 16 (Wednesday)

7:00 - 7:20 **Symposium 2 Preclinical Model for Pediatric Brain Tumors**

Sponsored by: St. Baldrick's Foundation

Moderator : *Daisuke Kawauchi (Japan)*

SYMP2-IS-06 Recapitulating developmental context using genetically engineered and patient-derived models of pediatric diffuse high-grade gliomas
Suzanne Baker (USA)

7:20 - 7:40 **Symposium 3 Precision Medicine**

Moderator : *Keita Terashima (Japan)*

SYMP3-IS-07 Precision Medicine in Pediatric Neuro-Oncology
Sabine Mueller (USA)

7:40 - 8:00 **Keynote 18 Preclinical models/Experimental Therapy/Drug Discovery**

Sponsored by: Children's Brain Tumor Network

Moderator : *Keita Terashima (Japan)*

MOD-IS-01 In Silico Drug Screening and System Biology Approach in Drug Repurposing
Ching Lau (USA)

8:00 - 8:20 **Keynote 19 Pediatric Neuropsychology**

Moderator : *Keita Terashima (Japan)*

PED-IS-01 Biological Substrates of Impaired Neurocognitive Functioning: Understanding the Late Effects of Surviving a Pediatric Brain Tumor
Stephen Sands (USA)

8:20 - 9:30 **Forum 4 Immunotherapy**

Moderator : *Naoya Hashimoto (Japan)*

8:20 - 8:40 *IMM-IS-01* Advances in cellular immunotherapy targeting pediatric brain tumors
Duane Mitchell (USA)

8:40 - 9:00 *IMM-IS-02* Today's immunotherapy for pediatric CNS tumors: briefly defining the Gordian Knot
Eugene Hwang (USA)

9:00 - 9:20 *IMM-IS-03* Nivolumab monotherapy and nivolumab in combination with ipilimumab in pediatric patients with high-grade primary central nervous system malignancies: safety and Pharmacokinetic results from CheckMate 908
Ira Dunkel (USA)

9:20 - 9:30 *IMM-QA-04* Panel discussion/Q&A

9:30 - 10:20 **Medulloblastoma Session**

Sponsored by: KiTZ Foundation

Moderator : *Daisuke Kawauchi (Japan)*

9:30 - 9:55 **Keynote 20**

MEDB-IS-01 (basic) Medulloblastomics 2020: biological and clinical insights from 1,000s of patients
Paul Northcott (USA)

9:55 - 10:20 **Keynote 21**

MEDC-IS-01 (clinical) Medulloblastoma – Biology informs Clinical Outcome
Amar Gajjar (USA)

10:20 - 10:40 **Keynote 22 Drug Delivery**

Moderator : *Daisuke Kawauchi (Japan)*

DRU-IS-01 Convection enhanced delivery (CED) in the brain stem of children with diffuse intrinsic pontine glioma (DIPG): beyond feasibility
Mark Souweidane (USA)

10:40 - 11:05 **Special Lecture 11**

Moderator : *Tomoki Todo (Japan)*

Sponsored by: Preston Robert Tisch Brain Tumor Foundation

SL11-IS-09 Brain immunology and immunotherapy in brain tumors.
David Ashley (USA)

11:05 - 11:30 **Keynote 23 Viral/gene Therapy**

Sponsored by: Denka Company Limited

Moderator : *Tomoki Todo (Japan)*

VIR-IS-LV-01 Results of phase II clinical trial of oncolytic herpes virus G47 Δ in adult patients with Glioblastoma (No On-Demand Program)
Tomoki Todo (Japan)

11:30 - 11:50 **Keynote 24 Radiation Oncology**

Sponsored by: FUJIFILM Corporation

Moderator : *Hiroshi Fuji (Japan)*

RAD-IS-01 Radiation Oncology in Pediatric Neuro-oncology
Thomas Merchant (USA)

11:50 - 12:30 **Keynote 25 Imaging**

Sponsored by: FUJIFILM Medical Solutions Co., Ltd

Moderator : *Hiroshi Fuji (Japan)*

IMA-IS-01 pH-weighted molecular imaging of brain tumors
Benjamin Ellingson (USA)

12:30 - 13:30 **Luncheon Seminar 3 Epilepsy**

Sponsored by: Eisai Co., Ltd

Moderator : *Ryo Nishikawa (Japan)*

LS-IS-LV-02 Tumor-related epilepsy and long-term epilepsy associated tumors in children: epilepsy surgeons' perspective (No On-Demand Program)
Kensuke Kawai (Japan)

13:30 - 13:50 **Closing Ceremony**

CC-01 Closing remarks
ISPNO2020 Award
Koichi Ichimura (Japan)

13:50 - 14:00 **Handover**

CC-02 Introduction to ISPNO2022 in Hamburg
Stefan Rutkowski (Germany)
Stefan Pfister (Germany)

14:00 - 14:10 **Adjourn**

On-demand Program at ISPNO 2020 will be available online and accessible from the URL and QR code below. The Main Program will be added and viewable after the meeting in January 2021.

Viewing Period: December 13 (Sun), 2020 – February 13 (Sat), 2021

URL: https://web-mice.jp/ispno2020/en/member/Login

Giving kids
with cancer
MORE THAN HOPE
Since 1998

THE Morgan Adams FOUNDATION
Funding Kids' Cancer Research

morganadamsfoundation.org

GOLD SPONSORS

THE Morgan Adams FOUNDATION

The Morgan Adams Foundation

The Morgan Adams Foundation has funded pediatric cancer research since 1998, giving kids with cancer and their families more than hope. Working with leading researchers and physicians, we fund new and innovative ideas that will improve cancer treatment effectiveness, overall outcomes, survival rates and quality of life while minimizing the devastating side effects current treatments have on children.

Apollo Proton Cancer Centre

The Most Advanced Cancer Centre- First Proton Centre in South Asia & The Middle East

The Apollo Proton Cancer Centre (APCC) is a 150-bed integrated cancer hospital offers state-of-the-art comprehensive cancer care. It is South Asia & the Middle East's first Proton Therapy and a major milestone in India's concerted focus to battle and conquer cancer. Powered by a cutting-edge multi room Proton Centre. Apollo Proton Cancer Centre is revolutionizing radiation oncology not just in India, but across the region. The hospital is a beacon of hope for over 3.5 billion people.

The advanced Proton Therapy at Apollo Proton Cancer Centre is complemented by a fully integrated treatment suite that offers the most advanced treatment procedures in surgical, radiation, medical oncology. True to the Apollo Pillars of Expertise and Excellence, the Centre brings together a powerful medical team helmed by some of the influential names in cancer care.

At the bedrock of APCC's approach to treat cancer is its robust multi-disciplinary platform; highly skilled professionals - united by expertise and commitment - come together to form Cancer Management Teams (CMT). Each CMT is focused on delivering the best possible outcomes to their patients.

---

abbvie

AbbVie Inc.

AbbVie is a research-driven global biopharmaceutical company headquartered in the United States.

At AbbVie, our mission is to have a remarkable impact on people's lives. We are passionate about advancing oncology research and development with an aim to transform standards of care for people living with cancer. Together, we harness our pioneering spirit, the focus and expertise of our team and partners, and cutting-edge resources to accelerate the delivery of advancements to patients and health care providers.

We're working to create solutions that go beyond treating the illness to have a positive impact on patients' lives, on societies—and on science itself.

At AbbVie, we see a future of possibility, where health is in reach and patient lives are improved.

- 175+ countries where our products help patients
- ~47,000 employees 14 countries with R&D and manufacturing facilities
- 60+ conditions treated
- Focus Areas: Immunology, Oncology, Neuroscience, Eye Care, Virology, Women's Health, Gastroenterology, Allergan Aesthetics

In Japan, more than 1,200 employees work at AbbVie. Putting patients at the center of what we do, we collaborate with stakeholders to address the challenges facing healthcare today and tomorrow. We market our products in focus therapeutic areas such as Immunology, Neonatology, Hepatitis, Neuroscience and Oncology.

Bristol Myers Squibb™

Bristol Myers Squibb

Children's Hospital Colorado

Registration fee (Category: Delegate 2) for clinicians, researchers and industry members who are from the low/lower-middle income countries assigned by the World Bank Group are partially supported by the donations from Children's Hospital of Colorado.

The Robert Connor Dawes Foundation

The Robert Connor Dawes Foundation works closely with organisations and researchers around the world to fast-track research funding and ultimately, improve treatment options.

We believe more brains are better than one, and we're proud to fund crucial research collaborations including, The AIM BRAIN Project, in partnership with ANZCHOG and DKFZ in Germany, and a CERN Fellowship currently underway in Cambridge.

SILVER SPONSORS

the Arnold & Winnie Palmer Foundation

The Arnold & Winnie Palmer Foundation champions the legacy of our founders. Through grantmaking and initiatives, we continue Arnold and Winnie's devotion to youth – encouraging strong character and supporting children facing health challenges – and honor their commitment to nature and its ability to enrich and heal us.

Chugai Pharmaceutical Co., Ltd.

Aflac Life Insurance Japan Ltd.
(アフラック)

illumina®

Illumina K.K.（イルミナ株式会社）

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. Our initial products enabled researchers to explore DNA in an entirely new way. Now, with more than 3400 patents worldwide and our sequencing-by-synthesis technology being used to generate over 90% of the world's sequencing data, we are leading the way, one genomic breakthrough at a time.

While the rate of progress continues to accelerate exponentially as we move towards precision medicine, we have only just begun to discover the true impact of genomics in areas we touch, including oncology, reproductive health, genetic disease, agriculture, microbiology, and beyond. Now, through innovation and collaboration, we are enabling genomic breakthroughs in immunotherapy, biomarker discovery, and therapy selection. The opportunity to transform tumor profiling with innovative assays that enable comprehensive genomic profiling, new companion diagnostic development, and liquid biopsy inspires us to push boundaries and drive innovation.

For more information please send us an email at contactJPN@illumina.com

---

Eisai Co., Ltd.

Eisai Co., Ltd

Pediatric Brain Tumor Foundation®

The Pediatric Brain Tumor Foundation

The Pediatric Brain Tumor Foundation is one of the world's leading nonprofit organizations dedicated to children and teens with brain tumors. Our mission is simple: Care. Cure. Thrive. We are committed to caring for families along their journey, funding and finding cures for all childhood brain tumors, and helping survivors and their families thrive. Our research investment strategy is guided by our mission to maximize the number of life-changing therapies moving from development through to commercialization to find targeted treatments for all children battling brain cancer. Since 1991, we have funded more than $46 million in scientific discovery through our Early Career Development awards, basic and translational science projects, clinical trial research and childhood cancer core infrastructure/education opportunities. Together, we are helping move the needle to find more effective treatments and a cure for all kids battling brain cancer. In addition, PBTF has connected thousands of families each year with patient and family education, financial relief, and a thriving community of support. A world without childhood brain tumors is possible when we stand together to effect real, meaningful change. We welcome all to support our mission to Care. Cure. Thrive. at www.curethekids.org.

The Childhood Brain Tumor Foundation

together, reaching for a cure!

The Childhood Brain Tumor Foundation

GENERAL SPONSORS

KiTZ (the Hopp Children's Cancer Center at the NCT Heidelberg)

The Hopp Children's Cancer Center Heidelberg (short: KiTZ) is at the same time a therapy and research center for oncological and haematological diseases in childhood and adolescence. More than 200 doctors, scientists and experts from all medical fields are working together to scientifically elucidate the biology of childhood cancer and severe blood diseases and to closely link promising research approaches with patient care - from diagnosis to treatment and aftercare. Children suffering from cancer, especially those for whom no established treatment options are available, are given an individual therapy plan at the KiTZ. Additionally, we have established so-called diagnostic platforms that allow for accurate diagnosis and treatment decisions, both in initial diagnosis and relapses (INFORM, MNP-IntR or PTT2.0). Many young patients are able to take part in clinical trials and thus gain access to new treatment options. The KiTZ thus assumes a model function in the transfer of research findings from the laboratory to the clinic.

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Medical U&A, Inc.

Passionately Put the Patient First

Each one of our products is not something we just sell.

We believe in, and treasure the bonds between people built up upon our products.

It is our mission to support every medical professional who are dedicated to saving lives at the medical front as well as to advance the health of patients and protect their smiles.

Medical U&A strives to deliver the highest quality products and services, contributing to, and playing an essential part in local community.

Canon Medical Systems Corporation

For more than 100 years, Canon Medical Systems has been at the cutting-edge of diagnostic imaging, creating healthcare solutions that can help enrich life for everyone.

In line with our long-standing commitment to excellence, we work hand-in-hand with leading clinical and academic partners to bring you the solutions that can help make a positive difference to you and your patients.

Canon Medical Systems has a comprehensive portfolio of advanced medical imaging from diagnostic and interventional imaging systems to healthcare IT solutions for the wider healthcare enterprise.

Recognized as a world leader in innovation, Canon Medical Systems continues to develop breakthrough technology and applications to support your imaging, diagnostic and therapeutic needs, all while optimizing patient outcomes.

・Whether that's cutting-edge AI-assisted imaging, intelligent healthcare IT, or even education and support, our promise remains the same: we will always help you put the wellbeing of your patients first.With Canon Medical, true innovation is made possible.

THERABIOPHARMA Inc.

THERABIOPHARMA Inc. has been established as a biotechnology venture company under the strong collaboration with Kyoto University. Our aim is to overcome the current fundamental issue of curcumin in the application for cancers treatment by providing the adequate concentration of free form curcumin for the carcinoma tissues to materialize curcumin's potential efficacies most effectively. The innovative R&D could deliver the most advantageous curcumin prodrug formula named curcumin monoglucuronide/TBP1901.

Curcumin, active form of TBP1901, showed the inhibition of proliferation for glioblastoma cell lines, and TBP1901 clearly demonstrated significant improvement of survival for Glioblastoma orthotopic graft mice (median control 32 days vs TBP1901 (high) 59 days).

The mechanism of action of TBP1901 is thought that it suppresses NF-κB activity through the inhibition of proteasome, IKK, TAK1. Injectable TBP1901 achieved 10,000 times higher free-form curcumin in blood stream than oral intake. This is the first observation to attain the concentration that reaches to show the antitumor activity in vitro and in vivo particularly for the Glioblastoma. In addition, 14-day repeated dose toxicity study has been conducted in rats and cynomolgus monkeys and a sufficient margin of dose was found between the pharmacological effect and the safety. TBP1901 is thought to expect to be developed and clinically applied as a glioblastoma-specific prodrug.

FUJIFILM Corporation

FUJIFILM group, Japan, brings continuous innovation with leading-edge, proprietary technologies by leveraging its photography expertise into a broad range of industries globally, including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies.

In the medical field, now we are developing AI technology to support diagnostic imaging, medical workflow, equipment warranty and service by expanding the AI technology under the "REiLI" brand; providing solutions designed to meet market demands. Going forward, as clinical information is increasingly viewed in the context of big data, AI technology will be applied to develop products that meet the different and challenging needs of the healthcare industry. Fujifilm aims to contribute to patient wellbeing through further improvements in healthcare efficiency and quality.

FUJIFILM Medical Solutions Co.,Ltd.

FUJIFILM Medical Solutions' ShadeQuest (image information integration system) is the best PACS for filmless operation, aiming to support the realization of "safe and secure medical care" and "medical care for patients" required by customers. ShadeQuest realizes comfortable speed, excellent operability, and optimal information management environment by highly linking each system component such as image storage, image display, and report creation.

ShadeQuest also supports daily work in line with the work of each occupation involved in radiation therapy, such as doctors, technicians, and nurses. In addition, information written by medical professionals of various occupations can be shared and confirmed, which is useful for the realization of patient-centered team medical care.

By linking online data with radiotherapy equipment, treatment planning equipment, imaging equipment, etc., distributed data and image information is acquired and centrally managed to build an integrated database of radiotherapy information and the entire hospital.

The Uehara Memorial Foundation (上原記念生命科学財団)

The Uehara Memorial Foundation was established in February 1985 to commemorate the 70th anniversary of the founding of Taisho Pharmaceutical Co., Ltd. and in memory of Shokichi Uehara, former President and Chairman of Taisho Pharmaceutical, who passed away in March 1983. Since the fiscal year of 1985, the Foundation's income from basic assets has been mainly utilized in providing grants for researchers, who are engaging in life sciences, as well as for the recognition of outstanding achievements in life science research (Uehara Award) and hosting of international symposia.

Denka Company Limited

Denka is a chemicals manufacturer developing business activities on a global scale across a wide range of fields, from inorganic and organic chemicals, to electronic materials and pharmaceuticals.

The Life Innovation Division is expanding beyond prevention and diagnosis into new fields such as cancer treatment drugs and services for providing diagnostic information.

In addition to influenza vaccine, diagnostic reagents, and macromolecular sodium hyaluronate preparations, the Life Innovation Division is working to expand this business field by providing products and services that promote the health of people around the world.

St. Baldrick's Foundation

The St. Baldrick's Foundation is a volunteer and donor powered charity committed to supporting the most promising research to find cures for childhood cancers and give survivors long and healthy lives. Grants are made for pediatric oncology research in many categories: email Grants@StBaldricks.org for more information.

Nationwide Children's Hospital

Lead by pediatric neurooncologist Dr. Maryam Fouladi and pediatric neurosurgeon Dr. Jeffery Leonard, the Neuro-Oncology Program is engaged through leadership and clinical trials in every major national neuro-oncology consortium including CONNECT, NEXT, PBTC, PNOC, and COG.

The Neuro-Oncology team provides international collaboration and support to peers in Central and South America through the Global Outreach Program, the first of its kind in pediatric-oncology. Through the Head Start 4 protocol, Nationwide Children's leads over 50 sites from around the world to improve the quality of survival and cure rates for young children with primitive neuro-ectodermal tumors. And we continue to treat patient families from around the globe including Canada, Poland, Saudi Arabia, South Africa, China, and throughout the United States.

Named to the Top 10 Honor Roll on U.S. News & World Report's 2020-21 list of "Best Children's Hospitals," Nationwide Children's Hospital is one of America's largest not-for-profit freestanding pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease.

Children's Brain Tumor Network

The Children's Brain Tumor Network's (CBTN) highly-committed community of expert researchers, clinicians, patient families, and support staff are dedicated to creating a world where no child dies or suffers from a brain tumor. The CBTN includes more than 20 member institutions located in Europe, Asia, Australia, and throughout the United States.

Discovering a cure for childhood brain cancer is a huge challenge; one that needs the dedication, brain power, and partnership of a global community to solve. The CBTN is leading the charge to share resources, discoveries, and expertise as broadly and as swiftly as possible, to researchers anywhere on earth. Highly-annotated samples of tissue and data are available at no cost to researchers to empower scientific discovery and collaboration across the scientific community. The CBTN's collaborative mission is redefining the traditional research model by accelerating the pace of discovery for all diagnosed children. To learn more, visit cbtn.org.

American Brain Tumor Association

Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research.

The ABTA has since expanded its mission and now provides comprehensive resources to support the complex needs of brain tumor patients and caregivers, across all ages and tumor types, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnoses, treatments and care.

DAIICHI SANKYO COMPANY, LIMITED

The Preston Robert Tisch Brain Tumor Center

Established in 1937, The Preston Robert Tisch Brain Tumor Center was one of the first brain tumor research and clinical programs in the United States. Since then, it has advanced to become one of the best pediatric and adult neuro-oncology programs in the world—leading the way in comprehensive care that combines research breakthroughs, clinical trials and the newest therapies. The National Cancer Institute (NCI) has given our center the highest rating of "outstanding" for each of the last 15 years.

Our patients are the reason we strive to deliver hope every day. They come here for the most advanced treatments. Often these are therapies that are not available anywhere else. Our center sees up to 900 new adult brain tumor patients and up to 75 new pediatric brain tumor patients per year from across the country and around the world. At the core of our success lies the commitment of countless physicians, nurses, researchers and staff – all with the goal to stand with our patients and families in the fight against brain tumors. We offer aggressive research and passionate care with a determination and clear focus to fight the disease.

S & Brain Corporation

Established in 2008, head office is located in Urayasu city in Chiba prefecture, Japan.

Business : Development of domestic instrument, mainly for Neuro Surgery

Main Product : Titanium Plate

Brand : SP Plate (sterile)

CHARLES RIVER LABORATORIES JAPAN, INC.

[Our passion comes from our commitment to helping you help others.]

At Charles River, we are passionate about our role in improving the quality of people's lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

[Oncology & Immuno-Oncology Studies]

To reach the clinic in record time, it's vital to test your oncology therapies in systems that reflect the disease seen in humans. Charles River offers a range of translational oncology studies, including in vitro assays and in vivo models, that mirror human cancers. Whether you want to test your therapy in a cell biology assay consisting of the elements of the tumor microenvironment or in models using real patient tissue, we can help.

[Virtual Exhibit]

Virtual Exhibit booths are now available for you to learn more about our research portfolio. Please visit our Virtual Exhibition.

AS ONE CORPORATION

NanoString Technologies, Inc.

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

AS ONE is NanoString's distributor in Japan, and today, in addition to exhibiting NanoString products, we are exhibiting 2D barcode tubes for sample management and related products.

Collaborative Ependymoma Research Network Foundation

The Collaborative Ependymoma Research Network (CERN) Foundation, a designated program of the National Brain Tumor Society, is dedicated to improving the lives of children and adults worldwide diagnosed with ependymoma. The CERN Foundation continues to advance ependymoma research by supporting scientific fellowships, clinical trials, and sponsoring professional conferences and symposia. We strive to bring awareness to the rare disease and improve the outcome and care of patients through education, referral support, and supported research efforts.

Sumitomo Dainippon Pharma Co., Ltd.

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery.

ZEISS Surgical Microscopes continuing to support you in advancing surgical visualization.

Our flagship visualization system, KINEVO® 900 from ZEISS is designed to deliver more functionalities than any surgical microscope today. ZEISS KINEVO 900 combines digital and optical visualization modalities, offers a unique Micro-Inspection Tool and will impress you with its Surgeon-Controlled Robotics.

1. Surgeon-Controlled Robotics adds a complete new level of ease to precise positioning. Imagine being able to focus and move around a structure to visualize the targeted anatomy.
2. The Digital Hybrid Visualization with integrated 4K technology of ZEISS KINEVO 900 welcomes you to a world of heads-up ocular-free surgery, giving you freedom of movement.
3. The unique, proprietary Micro-Inspection Tool from ZEISS complements intraoperative microsurgical visualization, enabling you to discover unexplored areas during the surgical intervention without additional footprint.

Aqua Clara, inc

東京南ロータリークラブ
The Rotary Club of Tokyo-South

Rotary Club of Tokyo South, which has a history of over 60 years, was established in 1950 after became independent from Rotary Club of Tokyo. Tokujiro Kanamori, who was deeply involved in the establishment of current Japanese constitution, assumed the Club as a First chairman. Since then, we have been inheriting his idea of liberal as a tradition of our Club.

Presently, there are over 200 members in our club.

Registration fee (Category: Delegate 2) for clinicians, researchers and industry members who are from the low/lower-middle income countries assigned by the World Bank Group are partially supported by the donations from The Rotary Club of Tokyo South Fellowship.

東京シティ日本橋ロータリークラブ
The Rotary Club of Tokyo City Nihonbashi

Our club was born in 1991 from the Rotary Club of Nihonbashi East, 68th club in the 2750 District and 1949th club in Japan.

And involved in the Ginza-Nihonbashi Group of the 2750 District.

Our regular meeting is held on Friday 12:30a.m. at the Royal Park Hotel (2-1-1 Kakigara-chou Chuou-ward Tokyo Met.)

the Tokyo Biochemical Research Foundation
（公益財団法人東京生化学研究会）

We are engaged in the following activities to support innovative research on pharmaceutical products.

- Research grants and incentives
- Subsidy for dispatching researchers to international conferences
- Invitation of overseas researchers and provision of scholarships
- Holding symposiums and academic conferences
- Reward to researchers

東京医科歯科大学脳神経外科同門会

The Tokyo Medical and Dental University Neurosurgery Alumni Society has been established in 1995 to support professional, scientific, and medical interactions among the members. Over the past five decades, about 200 of our members have built successful careers at academic, research and medical facilities across the nation. It is our great pleasure that Dr. Koichi Ichimura, who is our alumni, will serve as the chairman of ISPNO2020, and we sincerely wish the symposium will be fruitful for all the participants.

The Japan Pediatric Brain Tumor Research Fund
（小児脳腫瘍研究支援委員会）

Keiji Sano Lectureship

第 36 回日本脳腫瘍学会学術集会

第 37 回日本脳腫瘍学会学術集会

ながしま脳神経・頭痛クリニック

医療法人社団美心会

社会医療法人北斗

社会医療法人社団 森山医会

ユーシービージャパン 株式会社

株式会社エスアールエル

医療法人社団川善会六地蔵クリニック

医療法人千清會

合同会社 KIIN

合同会社 Be First

今村　純一郎

大野　喜久郎

小笠原　陽

金子　勝一

小柳　省一郎

酒葉　乃里子

清水　一秀

菅原　高志

鈴木　龍太

露無　松平

松井　秀文

Noboru Minowa

山本　徳治郎

東京日本橋ロータリークラブ

東京新橋ロータリークラブ

東京銀座ロータリークラブ

東京シティ日本橋ロータリー クラブ

ライオンズクラブ国際協会 330-A 地区

東京あけぼのロータリークラブ

（敬称略）

ISPNO2020 日本製薬団体連合会寄付

(List of Sponsors through the Federation of Pharmaceutical Manufacturers' Associations of JAPAN)

旭化成ファーマ株式会社
あすか製薬株式会社
アステラス製薬株式会社
アストラゼネカ株式会社
アルフレッサファーマ株式会社
栄研化学株式会社
エーザイ株式会社
エスエス製薬株式会社
MSD 株式会社
大塚製薬株式会社
株式会社大塚製薬工場
小野薬品工業株式会社
科研製薬株式会社
キッセイ薬品工業株式会社
杏林製薬株式会社
協和キリン株式会社
クラシエ製薬株式会社
興和株式会社
佐藤製薬株式会社
サノフィ株式会社
沢井製薬株式会社
参天製薬株式会社
株式会社三和化学研究所
塩野義製薬株式会社
ゼリア新薬工業株式会社
第一三共株式会社
大正製薬株式会社
大日本住友製薬株式会社
大鵬薬品工業株式会社
武田薬品工業株式会社
田辺三菱製薬株式会社
中外製薬株式会社
株式会社ツムラ
帝人ファーマ株式会社
テルモ株式会社
トーアエイヨー株式会社
東和薬品株式会社
鳥居薬品株式会社
日本化薬株式会社
日本ケミファ株式会社
日本新薬株式会社
日本製薬株式会社
日本臓器製薬株式会社
日本たばこ産業株式会社
日本ベーリンガーインゲルハイム株式会社
ニプロファーマ株式会社
バイエル薬品株式会社
扶桑薬品工業株式会社
ブリストル・マイヤーズ スクイブ株式会社
丸石製薬株式会社
マルホ株式会社
株式会社ミノファーゲン製薬
Meiji Seika ファルマ株式会社
持田製薬株式会社
株式会社ヤクルト本社
ロート製薬株式会社
わかもと製薬株式会社

（五十音順）

ISPNO Hamburg 2022

Save the Date: June 13-15, 2022!

Copyright Mediaserver Hamburg

We are looking forward to welcoming you to the 20th International Symposium on Pediatric Neuro-Oncology - June 13-15, 2022 - Hamburg, Germany

Chairs: Stefan Rutkowski, Hamburg
Stefan Pfister, Heidelberg

Venue: Congress Center Hamburg

UKE HAMBURG

KINDER UKE

KiTZ Hopp Children's Cancer Center Heidelberg

dkfz. GERMAN CANCER RESEARCH CENTER IN THE HELMHOLTZ ASSOCIATION
Research for a Life without Cancer

私たち認定NPO法人ゴールドリボン・ネットワークは

小児がんの子ども達が安心して笑顔で生活できる社会

を創ることを目指して活動する**小児がん支援団体**です

Gold Ribbon Network (GRN) is a non-profit organization dedicated to supporting children with cancer and their families. We aim to create a society where children with cancer are able to live their lives with comfort and security.

■活動事例

〈ゴールドリボン〉
研究助成

小児がんを治る病気にするため、治癒率向上のための研究への助成と研究者の海外留学を支援しています。
2020年は、18の研究及び研究団体更には留学生1名に対し、計1590万円を助成しました。

〈ゴールドリボン〉
小児がん交通費等補助金制度

小児がんの治療にかかる費用で最も負担の大きい交通費や付添いの方の宿泊費を助成する制度です。
自宅から100キロ以上離れている病院で入院や治療をする場合の交通費や付添いの方の宿泊費を年間1家族50万円を限度として支援しています。
2020年1~10月実績／140件　計20,282,000円

〈はばたけ！ ゴールドリボン〉
奨学金制度（給付型）

小児がん経験者の方で大学や専門学校への進学を希望されている方を支援する事を目的とする月額4万円で、返済不要の給付型奨学金制度です。
2020年度の奨学生人数36名　支払総額1728万円（予定）

小児がん経験者の方への 就労移行支援　等

■ What we do

〈GRN〉 Research Grant

Aiming to ultimately conquer childhood cancer, we provide funding for research in childhood cancer and study abroad for one year for a researcher every year. In 2020, we granted altogether 15,900,000 yen ($152,300) to 18 researches and a study abroad.

〈GRN〉 Hospital Visit Expenses

It is often the case in Japan that travel and accomodation expenses for hospital visits are the major costs families spend to treat childhood cancer. We cover hospital visit expenses for 100km plus travel and also accommodation for accompanying family members up to 500,000 yen per year per patient. From January to October 2020, we helped 140 cases in total of 20,282,000 yen ($194,300).

〈GRN〉 Scholarship

Cancer survivors will be awarded scholarships for universities, colleges or vocational schools. We grant annual 480,000 yen per student for the minimum of mandatory period required for the graduation. In 2020 we awarded 36 students, 17,280,000 yen ($165,500) in total.

Employment Assistance etc.

1＄＝104.4 yen



Gold Ribbon Network
認定NPO法人 ゴールドリボン・ネットワーク

http://www.goldribbon.jp
〒171-0021　東京都豊島区西池袋 2-21-8 目白欅マンション 204 号　TEL03-5944-9922　FAX03-5944-9923

SURGIFLO®
Hemostatic Matrix Kit

サージセルの伝統を継承するとともに、
異なる原理の止血材を通じ、日本の医療へ新たな価値を提案します。

ETHICON
PART OF THE Johnson&Johnson FAMILY OF COMPANIES

製造販売元:ジョンソン・エンド・ジョンソン株式会社 メディカル カンパニー
〒101-0065 東京都千代田区西神田3丁目5番2号
高度管理医療機器　販売名:サージフロー®　承認番号:23100BZX00112000

125655-191015

©J&JKK 2019

大日本住友製薬

造血幹細胞移植前治療薬

薬価基準収載

リサイオ®点滴静注液100mg

RETHIO®

注射用チオテパ

劇薬　処方箋医薬品注)　注)注意－医師等の処方箋により使用すること

効能･効果、用法･用量、警告･禁忌を含む使用上の注意等については、
添付文書をご参照ください。

製造販売元（資料請求先）
大日本住友製薬株式会社
〒541-0045　大阪市中央区道修町 2-6-8

〈製品に関するお問い合わせ先〉
くすり情報センター
TEL　0120-034-389
受付時間／月～金 9:00～17:30（祝・祭日を除く）
【医療情報サイト】https://ds-pharma.jp/

2019年5月作成

子どもたちの笑顔のために、
続けてきたことがある、始めていくことがある。

小児がんは15歳未満の子どもに起こる悪性腫瘍の総称です。大人と比べて入院日数が
長期にわたることが多く、自宅から離れた病院で闘病生活を送らなければならないこともあります。

アフラックはこれまでも、社員・アソシエイツ（販売代理店）がひとつになって、
小児がんの子どもたちとそのご家族を支えるさまざまな活動を続けてきました。
そして2019年から、My Special Aflac Duckを通じた新しい活動を始めています。

2019～

小児がんの子どもたちの「今」の気持ちに寄り添う。

My Special Aflac Duck

病院での長い入院生活。My Special Aflac Duckは、
治療に取り組む子どもたちの心に寄り添うために、
米国で医療関係者、ロボット開発企業とアフラックが共同開発した
アヒル型ロボットです。2019年から日本の小児がん診療病院等への
寄贈を進めています。

2006～

小児がんの子どもたちを「社会」で支えていく。

ゴールドリボン運動

小児がんを広く社会に知ってもらうことで
子どもたちを支える社会の実現を目指します。
ウォーキングイベントなどの啓発活動や
寄付・募金活動を展開しています。

2001～

がんと闘うご家族の「日々」をサポートする。

アフラック ペアレンツハウス

小児がんなどの難病の子どもたちと、そのご家族をサポートする総合支援センター。
遠隔地から治療に訪れる子どもたちやご家族の宿泊、専門カウンセラーによる
相談支援などを行っています。

1995～

小児がんを経験した子どもたちや、
親をがんで亡くした子どもたちの「明日」を応援する。

アフラック小児がん経験者・がん遺児奨学金制度

高校生を対象とした返還不要の奨学金制度。
これまでに支援した奨学生は、累計2,800人を超えています。
※小児がん経験者を対象とした奨学金制度は、2014年から行っています。

アフラックの
小児がん支援活動

「生きる」を創る。

Aflac

Tin filter technology

一般撮影レベルの被ばくで CT検査が可能になるのか?

www.siemens-healthineers.com/jp

Tube Voltage：Tin filter 110kV
CTDIvol:0.11mGy
DLP:4mGy・cm
Effective Dose：0.05mSv*

*conversion factor: 0.014
(ICRP Publication102)
Courtesy of Sendainakae
Hospital, Miyagi, Japan

Tin filter technologyは画像に影響のないX線を効率的にカットするハードウェア技術です。
CT装置にはこれまでもさまざまな被ばく低減機構が開発され、活用が進んでいますが
Siemens HealthineersはTin filter technologyを加えることで一般撮影レベルの被ばく*でCT検査を可能にしました。

* Radiology, 2008 Jul; 278によると、一般的な胸部レントゲン撮影の被ばく線量は0.1 mSv（実効線量換算）とされています

SIEMENS Healthineers

Healthcare for You

私たちエスアールエルは、
医療機関から預かる、
患者さまの検体を通して、
いのちの未来を見つめています。

SRL
Communication for Health

株式会社 エスアールエル

H.U.GROUP

2020年7月1日、みらかホールディングスは
H.U.(エイチ・ユー)グループホールディングスへ社名変更いたしました。

富士レビオ株式会社

NS Nihon Stery 日本ステリ株式会社

株式会社 エスアールエル　本社 〒163-0409 東京都新宿区西新宿2-1-1新宿三井ビルディング　TEL.03-6279-0900 www.srl-group.co.jp

Codman
SPECIALTY SURGICAL
A DIVISION OF INTEGRA LIFESCIENCES

「攻め」と「守り」を巧みに操る

Masterful Maneuverability to Conquer and Protect

超音波吸引器

CUSA® Clarity

INTEGRA
LIMIT UNCERTAINTY®

製造販売元
Integra Japan株式会社
〒107-0052　東京都港区赤坂1丁目7番1号 赤坂榎坂ビル
TEL: 03-6809-0235　FAX: 03-6809-0236

販売名：超音波手術器　CUSA Clarity
承認番号：23000BZX00065000
クラス分類：高度管理医療機器　クラスⅢ
特定保守管理医療機器

meiji



光線力学的療法用剤
劇薬、処方箋医薬品(注1)
薬価基準収載
注射用レザフィリン®100mg
LASERPHYRIN® 100mg FOR INJECTION
注射用タラポルフィンナトリウム
注1)注意－医師等の処方箋により使用すること

PDT半導体レーザ
PDレーザ BT
<承認番号 22500BZX00420000>

※「効能・効果」、「用法・用量」、「効能・効果に関連する使用上の注意」、「用法・用量に関連する使用上の注意」、「禁忌を含む使用上の注意」など、詳細は製品の添付文書等をご参照ください。

製造販売元
Meiji Seika ファルマ株式会社
東京都中央区京橋 2-4-16
https://www.meiji-seika-pharma.co.jp/

〈文献請求先及び問い合わせ先〉
Meiji Seika ファルマ株式会社 くすり相談室
〒104-8002 東京都中央区京橋 2-4-16
フリーダイヤル(0120)093-396
電話(03)3273-3539、FAX(03)3272-2438

作成：2020.11

医療機器・医療材料、福祉用具の
スペシャリストとして。
常に迅速丁寧に、より質の高い商品・サービスを提供し
お取引先様の期待にお応えします。

医療機器・医療材料 販売
株式会社 いわしや盛田器械店
本社/〒354-0018 埼玉県富士見市西みずほ台1-2-6 Uchidaビル2階
TEL(049)293-2277 FAX(049)254-7032
毛呂山営業所/〒350-0467 埼玉県入間郡毛呂山町岩井東一丁目5-12
TEL(049)276-1910 FAX(049)276-1911

Quality of Life

患者さんの健やかな笑顔のために。

一人でも多くの方が生きることを前向きにとらえ、
しあわせを感じられるように。

帝人ファーマ株式会社
東京都千代田区霞が関3-2-1（霞が関コモンゲート西館）
http://www.teijin-pharma.co.jp/

Otsuka-people creating new products for better health worldwide

Thinking Holistically About Health Across Our Two Core Businesses

Nutraceutical Business
Maintenance and improvement of everyday health

Pharmaceutical Business
From diagnosis to treatment

Otsuka Otsuka Pharmaceutical Co., Ltd.
https://www.otsuka.co.jp/

nihon medi+physics

明日の幸せを願い、「診る」そして「治す」核医学。

私たちは、がんや心臓病、脳血管疾患および認知症などの早期発見に役立つSPECT・PET検査用放射性医薬品や、がん治療用の医療機器、治療薬などの創出を通じ、これからも皆様の健康に貢献します。

〒136-0075 東京都江東区新砂3丁目4番10号 TEL (03) 5634-7006 (代) **https://www.nmp.co.jp/**
日本メジフィジックス株式会社
2019年12月作成

Neuro-Oncology Care Done Differently at Nationwide Children's Hopsital

Internationally Respected Leadership

Maryam Fouladi, MD, MSc, FRCP, an internationally known expert in pediatric brain tumors, has joined Nationwide Children's as co-director of the Neuro-Oncology Program alongside neurosurgical co-director Jeff Leonard, M.D. Together to continue to lead an unprecedented program built by previous co-director and Nationwide Children's Head Start Clinical Trials PI Jonathan Finlay, MB, ChB, FRCP.

World Renowned Research Programs

Nationwide Children's is connected and well represented in national pediatric neuro-oncology consortiums including:

- Collaborative Network for Neuro-oncology Clinical Trials (CONNECT)
- NEXT Consortium and Head Start Clinical Trials
- Pediatric Brain Tumor Consortium (PBTC)
- Pacific Pediatric Neuro-Oncology Consortium (PNOC)
- Children's Oncology Group (COG)

Global Reach

Treating neuro-oncology patients from around the world, Including:

Saudi Arabia • Canada • South Africa • China • Poland • Throughout the United States

14
PEDIATRIC NEURO-ONCOLOGISTS AND NEUROSURGEONS

20+
ONGOING NEURO-ONCOLOGY CLINICAL TRIALS

50+
CENTERS WORLDWIDE IN THE HEAD START 4 CLINICAL TRIAL

To learn more about our program or to connect with our team, visit NationwideChildrens.org/Specialties/Neuro-Oncology

NATIONWIDE CHILDREN'S®
When your child needs a hospital, everything matters.

Dr. David Ashley, Director,
and the faculty and staff of

The Preston Robert Tisch
Brain Tumor Center at Duke

are honored to sponsor the

19th Annual
International Symposium on
Pediatric Neuro-Oncology

The Preston Robert Tisch
Brain Tumor Center

CONNECTING BRAINS AROUND THE WORLD

The Robert Connor Dawes Foundation works closely with organisations and researchers around the world to fast-track research funding and ultimately, improve treatment options.

We believe more brains are better than one, and we're proud to fund crucial research collaborations including, The AIM BRAIN Project, in partnership with ANZCHOG and DKFZ in Germany, and a CERN Fellowship currently underway in Cambridge.

Learn more at Rcdfoundation.org

SUPPORTING PEDIATRIC BRAIN CANCER MATTERS IN THE AREAS OF RESEARCH, CARE & DEVELOPMENT

ROBERT CONNOR DAWES FOUNDATION

ROBERT CONNOR DAWES RCD Foundation SUPPORTING BRAIN MATTERS

日本標準商品分類番号 874291

抗悪性腫瘍剤／チロシンキナーゼ阻害剤

劇薬、処方箋医薬品*

薬価基準収載

ロズリートレク®カプセル100mg、200mg

ROZLYTREK® Capsules entrectinib

エヌトレクチニブカプセル

*注意－医師等の処方箋により使用すること ®F.ホフマン・ラ・ロシュ社(スイス)登録商標

効能又は効果、効能又は効果に関連する注意、用法及び用量、用法及び用量に関連する注意、警告、禁忌を含む使用上の注意等は製品添付文書をご参照ください。

製造販売元 中外製薬株式会社 〒103-8324 東京都中央区日本橋室町2-1-1 (文書請求先及び問い合わせ先) メディカルインフォメーション部 TEL.0120-140-564 FAX.0120-189-705 (販売情報提供活動に関する問い合わせ先) https://www.chugai-pharm.co.jp/guideline/

ロシュ グループ

2019年11月改訂

子どもたちの笑顔のために、続けてきたことがある、始めていくことがある。

小児がんは15歳未満の子どもに起こる悪性腫瘍の総称です。大人と比べて入院日数が長期にわたることが多く、自宅から離れた病院で闘病生活を送らなければならないこともあります。

アフラックはこれまでも、社員・アソシエイツ（販売代理店）がひとつになって、小児がんの子どもたちとそのご家族を支えるさまざまな活動を続けてきました。

そして2019年から、My Special Aflac Duckを通じた新しい活動を始めています。

2019～

小児がんの子どもたちの「今」の気持ちに寄り添う。

My Special Aflac Duck

病院での長い入院生活。My Special Aflac Duckは、治療に取り組む子どもたちの心に寄り添うために、米国で医療関係者、ロボット開発企業とアフラックが共同開発したアヒル型ロボットです。2019年から日本の小児がん診療病院等への寄贈を進めています。

2006～

小児がんの子どもたちを「社会」で支えていく。

ゴールドリボン運動

小児がんを広く社会に知ってもらうことで子どもたちを支える社会の実現を目指します。ウォーキングイベントなどの啓発活動や寄付・募金活動を展開しています。

2001～

がんと闘うご家族の「日々」をサポートする。

アフラック ペアレンツハウス

小児がんなどの難病の子どもたちと、そのご家族をサポートする総合支援センター。遠隔地から治療に訪れる子どもたちやご家族の宿泊、専門カウンセラーによる相談支援などを行っています。

1995～

小児がんを経験した子どもたちや、親をがんで亡くした子どもたちの「明日」を応援する。

アフラック小児がん経験者・がん遺児奨学金制度

高校生を対象とした返還不要の奨学金制度。
これまでに支援した奨学生は、累計2,800人を超えています。
※小児がん経験者を対象とした奨学金制度は、2014年から行っています。

アフラックの小児がん支援活動

「生きる」を創る。 Aflac

ARNOLD & WINNIE PALMER FOUNDATION

The Arnold & Winnie Palmer Foundation champions the legacy of our founders. Through grantmaking and initiatives, we continue Arnold and Winnie's devotion to youth – encouraging strong character and supporting children facing health challenges – and honor their commitment to nature and its ability to enrich and heal us.

www.PalmerFoundation.org

The
Childhood Brain Tumor
Foundation

together, reaching for a cure!

Pediatric Brain Tumor Foundation

PLGA Fund
Pediatric Brain Tumor Foundation
FUNDING RESEARCH ▶ FINDING CURES

Transforming how childhood brain tumors are treated and patient families cared for.

CARE. PBTF is a critical point of care for families, empowering them with patient and family education, financial relief and emotional support.

CURE. PBTF provides strategic leadership to fund key gaps in research and drug development pipelines, accelerate therapies, and cure all pediatric brain tumors.

THRIVE. PBTF offers a thriving community for kids, survivors and families in need, walking beside them from diagnosis through treatment and beyond.

A world without childhood brain tumors IS possible.
Join us in our mission to CARE, CURE, THRIVE.

www.curethekids.org | info@curethekids.org

Bristol Myers Squibb™

Eisai

hhc
human health care

患者様の
想いを見つめて、
薬は生まれる。

ヒューマン・ヘルスケア企業
エーザイ

Practical Implementation of DNA Methylation and CNV Based CNS Tumor Testing (Virtual Peer-to-Peer Meeting)

Presenters:

Felix Sahm, MD, PhD
German Cancer Research Center (DKFZ), Heidelberg, Germany

Eric Vail, MD
Cedars-Sinai, USA

David Solomon, MD, PhD
UCSF Clinical Cancer Genomics Laboratory, USA

Andreas von Deimling, MD
German Cancer Research Center (DKFZ), Heidelberg, Germany

https://jp.illumina.com/events/seminars/2020/dna-methylation-peer-to-peer.html

Illumina K.K.
Mita Bellju Building 22F
5-36-7 Shiba, Minato-ku, Tokyo 108-0014, Japan
jp.illumina.com

illumina®

Doing everything we can for patients who are waiting

AbbVie GK
3-1-21 Shibaura, Minato-ku
Tokyo 108-0023, Japan
https://www.abbvie.co.jp/

abbvie

People. Passion. Possibilities.

A Top-Ranked Pediatric Cancer Program

BEST CHILDREN'S HOSPITALS
U.S.News & WORLD REPORT
CANCER 2020-21

Children's Hospital Colorado ranked #6 in the nation according to *U.S. News & World Report*, with high marks in all 10 recognized specialties, seven of those in the top 10. And this year we're especially proud to announce that our Center for Cancer and Blood Disorders program is ranked at #9 in cancer care.

This year, we're the only top 10 hospital within an 850-mile radius. With a relentless focus on quality and safety, a commitment to research and discovery, and the deep expertise that comes from seeing and treating the most kids in the region, we remain on the forefront of delivering some of the best outcomes in the nation to the most complex patients.

Children's Hospital Colorado
Here, it's different.

© Children's Hospital Colorado 2020 All rights reserved. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. • ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-1234. • CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-1234. CCBD-570738-2020-11